Single-Domain Anti-PDL1 Antibodies for High-Affinity Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for the development of PDL1-targeting molecules and methods for cancer treatment, as existing antibody inhibitors of the PD1/PDL1 interaction have limitations in clinical efficacy.
Innovation Solution
Development of isolated monoclonal antibodies and antibody derivatives that bind specifically to PDL1 with high affinity, including monospecific and multispecific antibodies, which can target tumor cells and enhance immune responses, utilizing single domain antibodies and multispecific formats to improve anti-tumor efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibody inhibitors of the PD1/PDL1 interaction are used for treating cancer, then immune escape can be inhibited and antitumor activity can be mediated, but clinical efficacy remains limited
Solution Approach 1:
The patent develops multispecific antibodies that can bind to multiple targets simultaneously (PDL1 and other tumor-associated antigens), enabling a single antibody molecule to perform multiple functions: tumor targeting, immune activation, and enhanced specificity. This multi-functionality directly addresses the limited clinical efficacy by providing more comprehensive tumor coverage and reduced escape mechanisms
Solution Approach 2:
The patent employs single domain antibodies (sdAbs) with optimized binding characteristics to achieve high-affinity, specific binding to PDL1. The sdAb format allows for improved tissue penetration and localized action at the tumor site, enhancing the reliability of immune activation while maintaining the ability to adapt to different tumor microenvironments
2Reliability
If single domain antibodies are used to bind PDL1, then high affinity binding can be achieved, but the complexity of antibody structure is reduced
Solution Approach 1:
The patent extracts and utilizes only the essential antigen-binding domain (single domain antibody) without the full antibody structure. This extraction maintains the critical function of high-affinity PDL1 binding while eliminating unnecessary structural complexity, resulting in sdAbs with molecular weights of 15-25 kDa that can penetrate tissues more effectively and bind with high affinity to PDL1
Solution Approach 2:
The patent changes the structural parameters of the antibody from full-length (150 kDa) to single domain (15-25 kDa), fundamentally altering the physical and chemical properties. This parameter change enables high affinity binding through optimized CDR regions while the reduced size provides improved pharmacokinetic properties, tissue penetration, and manufacturing simplicity
3Reliability
If multisspecific antibodies are developed to target multiple antigens, then anti-tumor efficacy can be improved, but the manufacturing complexity increases
Solution Approach 1:
The patent merges multiple antigen-binding specificities into a single multispecific antibody molecule, where one antibody can simultaneously bind to PDL1 and other tumor-associated antigens. This merging approach improves anti-tumor efficacy by targeting multiple pathways and reducing escape mechanisms, while the modular sdAb construction facilitates relatively straightforward manufacturing compared to traditional bispecific antibody approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide enhanced tumor targeting and immune response, leading to improved anti-tumor efficacy and potential therapeutic benefits for various cancer types, including those with high microsatellite instability.
Implementation Method 1
isolated monoclonal antibodies and antibody derivatives that bind specifically to PDL1 with high affinity
Implementation Method 2
Interaction of this ligand with its receptor PD1 inhibits T cell activation and cytokine secretion
Data Source
AI summary
The present disclosure relates to antibodies and antibody derivatives that bind to PDL1 and methods of using the same. In certain embodiments, the antibody or antibody derivative disclosed herein comprises a single domain antibody that binds to PDL1.